UCLA Study Reveals Favorable Revascularization Rates of Versi Retriever in Acute Ischaemic Stroke

Dec 16, 2018 | Cardiovascular, Medical Device, Stroke

An ischaemic stroke is where the blood supply to the brain is blocked by a blood clot or clump of fat. This staves the brain of the oxygen and nutrients its needs, which damages the brain cells. It is of immediacy to get this treated. Nearly 800,000 people in the U.S. have a stroke every year. Stroke is the fifth leading cause of death in the U.S. killing nearly 130,000 people annually.   

Laguna Hills, California-based NeuroVasc Technologies was founded in 2015 and has raised approximately $8.8 million according to website Crunchbase. A medical device start-up, it is dedicated to improving the treatment of neurovascular conditions with a focus on ischemic stroke. The company has developed the Versi Mechanical Thrombectomy System—used for clot removal from the blood vessels of the brain during an acute ischemic stroke. The device has not been cleared by the FDA for use in the United States.

Recently, a UCLA-led clinical trial revealed that the first-in-man results of the Vertsi Retriever in acute ischaemic storke patients with large vessel occlusions demonstrate a promising safety profile and efficacious revascularization rates. The study results were recently published in the Journal of NeuroInterventional Surgery. Follow the link to the Neuro News International story for more details.

Lead Research/Investigator

Satoshi Tateshima, UCLA


Pin It on Pinterest